International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“A new treatment option has entered the landscape for patients with advanced EGFR-mutant NSCLC.
In the latest Lung Cancer Considered, Dr. Narjust Florez sits down with Dr. Jacob Sands to review the FDA approval of datopotamab deruxtecan for patients who have progressed on both EGFR-targeted therapy and platinum-based chemotherapy.
The conversation highlights trial data, patient selection, and what this new approval means for clinical practice.
More posts featuring IASLC.